Publication:

Latitud total hip replacement system in younger and older patients: a comprehensive multi-center assessment of clinical and functional outcomes

Background Total hip arthroplasty (THA) is a standard treatment for end-stage hip disease. With rising demand across age groups, evaluating implant performance in younger and older patients is important. The Latitud total hip replacement system (HRS) is a novel implant,with no data on its safety and performance in younger patinets. Hence, We aimed to evaluate safety and functional outcomes of the Latitud HRS in younger (≤40 years) and older (>40 years) patients undergoing unilateral or bilateral THA.

Methods This prospective multicenter study across 11 Indian centers enrolled 192 patients undergoing primary THA with the Latitud HRS, followed for 2 years. Primary outcomes were implant survivorship and revision rates; secondary outcomes were clinical improvement using Harris Hip Score (HHS), Oxford Hip Score (OHS), and adverse events.

Results Of 192 patients, 67 were ≤40 years (55 unilateral, 12 bilateral) and 125 were >40 years (119 unilateral, 6 bilateral). Avascular necrosis predominated in younger patients, while osteoarthritis dominated older cases. At 2 years, OHS improved significantly in all groups: younger (unilateral 10.18±3.39 to 43.76±4.8; bilateral 8.75±2.83 to 43.08±4.01) and older (unilateral 8.06±4.67 to 43.69±4.68; bilateral 10.83±0.98 to 44.67±5.82). HHS also increased substantially: younger (unilateral 23.58±8.55 to 84.9±9.79; bilateral 19.71±10.93 to 89.4±5.07) and older (unilateral 18.16±12.13 to 86.38±7.89; bilateral 27.09±4.77 to 90). Implant survivorship was 100% in all except older unilateral (99.15%) due to one liner breakage.

Conclusion The Latitud HRS demonstrated excellent survivorship and functional recovery across both age groups, supporting its safety and durability in Indian patients, including younger adults with high functional demands.